Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 9/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4403519 | 0.94 | NAMPT (0.46) | NAMPTTPSAB1RAB9ACHRNB2CHRNA7 | |
| SCHEMBL648783 | 0.92 | SMN1; SMN2 (0.46) | NAMPTTPSAB1RAB9ASMN1; SMN2HTT | |
| SCHEMBL649505 | 0.92 | NAMPT (0.42) | NAMPTTPSAB1RAB9AMEN1KMT2A | |
| SCHEMBL16927791 | 0.87 | SMN1; SMN2 (0.45) | NAMPTTPSAB1RAB9ACHRNB2CHRNA7 | |
| SCHEMBL16927797 | 0.87 | CHRNB2 (0.42) | NAMPTTPSAB1RAB9ACHRNB2CHRNA7 | |
| SCHEMBL4458563 | 0.85 | DRD4 (0.53) | CHRNB2CHRNA7CHRNA4KDM4EALDH1A1 | |
| SCHEMBL4402680 | 0.84 | CHRNB2 (0.44) | NAMPTCHRNB2CHRNA7CHRNA4SMN1; SMN2 | |
| SCHEMBL648628 | 0.83 | CHRNB2 (0.41) | NAMPTRAB9ACHRNB2CHRNA7CHRNA4 | |
| SCHEMBL648627 | 0.83 | CHRNB2 (0.41) | NAMPTRAB9ACHRNB2CHRNA7CHRNA4 | |
| SCHEMBL4451000 | 0.80 | ACHE (0.47) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115838-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | CS, SHMT2, GOT2 | NAMPT 291/4885TPSAB1 3167/4885RAB9A 4168/4885 |
| US-20120115838-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | PRKAA1, PRKAA2, PRKAG1 | NAMPT 307/4885TPSAB1 3321/4885RAB9A 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.